KMID : 0361519990100020166
|
|
Korean Journal of Psychopharmacology 1999 Volume.10 No. 2 p.166 ~ p.172
|
|
Agranulocytosis and Neutropenia in Clozapine-Treated Patients
|
|
Cho Hyun-Sang
An Suk-Kyoon Kim Chan-Hyung Lee Hong-Shick
|
|
Abstract
|
|
|
Objective£ºClozapine is effective in the treatment of refractory schizophrenic patients, but can cause reversible and fatal bood dyscrasias. This study documents the incidence of agranulocytosis and neutropenia and the characteristics of patients with clozapine-induced agranulocytosis.
Method£ºAn analysis was made of the hematological, demographic, and other characteristics data from Clozaril Patient Monitoring System (CPMS) data on 2139 patients on clozapine over about 3 years in Korea.
Results£ºDuring the study period, agranulocytosis developed in 11 patients and 9 (81.8%) patients occurred within 18 weeks. The cumulative incidence of this side effect was 0.57% at 6 months and 0.65% at 1 to 3 years and the crude incidence was 0.51%. Neutropnia occurred in 157 patients and 114 (72.6%) ones developed within 18 weeks. The crude incidence of this blood abnormality was 6.9% at 1 year and 7.3% at 3 years. The cumulative incidence was 9.0% at 1 year and 28.7% at 3 years. The hazard rates for agranulocytosis and neutropenia peaked during the 3rd month and 2nd month, respectively.
Conclusions£ºThese results showed that the incidence of agranulocutosis in Korea may be lower than in USA and UK, at least during the early years of clozapine marketing. Also those suggest that the CPMS in Korea serves as a effective early warning system to promote the safety and benefits of clozapine.
|
|
KEYWORD
|
|
Clozapine, Agranulocytosis, Neutropenia, Clozapine,
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|